1269 related articles for article (PubMed ID: 30064501)
21. Inhibition of Class I Histone Deacetylases 1 and 2 Promotes Urothelial Carcinoma Cell Death by Various Mechanisms.
Pinkerneil M; Hoffmann MJ; Deenen R; Köhrer K; Arent T; Schulz WA; Niegisch G
Mol Cancer Ther; 2016 Feb; 15(2):299-312. PubMed ID: 26772204
[TBL] [Abstract][Full Text] [Related]
22. Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro.
Freese K; Seitz T; Dietrich P; Lee SML; Thasler WE; Bosserhoff A; Hellerbrand C
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635225
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylase inhibitors exert anti-tumor effects on human adherent and stem-like glioma cells.
Was H; Krol SK; Rotili D; Mai A; Wojtas B; Kaminska B; Maleszewska M
Clin Epigenetics; 2019 Jan; 11(1):11. PubMed ID: 30654849
[TBL] [Abstract][Full Text] [Related]
24. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
[TBL] [Abstract][Full Text] [Related]
25. Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Wanek J; Gaisberger M; Beyreis M; Mayr C; Helm K; Primavesi F; Jäger T; Di Fazio P; Jakab M; Wagner A; Neureiter D; Kiesslich T
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321986
[TBL] [Abstract][Full Text] [Related]
26. Histone Deacetylase Inhibitor, Trichostatin A, Synergistically Enhances Paclitaxel-Induced Cytotoxicity in Urothelial Carcinoma Cells by Suppressing the ERK Pathway.
Hsu FS; Wu JT; Lin JY; Yang SP; Kuo KL; Lin WC; Shi CS; Chow PM; Liao SM; Pan CI; Hong JY; Chang HC; Huang KH
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30866433
[TBL] [Abstract][Full Text] [Related]
27. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
28. Transcriptomic and genomic studies classify NKL54 as a histone deacetylase inhibitor with indirect influence on MEF2-dependent transcription.
Minisini M; Di Giorgio E; Kerschbamer E; Dalla E; Faggiani M; Franforte E; Meyer-Almes FJ; Ragno R; Antonini L; Mai A; Fiorentino F; Rotili D; Chinellato M; Perin S; Cendron L; Weichenberger CX; Angelini A; Brancolini C
Nucleic Acids Res; 2022 Mar; 50(5):2566-2586. PubMed ID: 35150567
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
Zhou Q; Dalgard CL; Wynder C; Doughty ML
BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
[TBL] [Abstract][Full Text] [Related]
30. Characterization of Histone Deacetylase Expression Within In Vitro and In Vivo Bladder Cancer Model Systems.
Buckwalter JM; Chan W; Shuman L; Wildermuth T; Ellis-Mohl J; Walter V; Warrick JI; Wu XR; Kaag M; Raman JD; DeGraff DJ
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137849
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
32. HDAC gene expression in pancreatic tumor cell lines following treatment with the HDAC inhibitors panobinostat (LBH589) and trichostatine (TSA).
Mehdi O; Françoise S; Sofia CL; Urs G; Kevin Z; Bernard S; Igor S; Anabela CD; Dominique L; Eric M; Ali O
Pancreatology; 2012; 12(2):146-55. PubMed ID: 22487525
[TBL] [Abstract][Full Text] [Related]
33. Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression.
Jaguva Vasudevan AA; Hoffmann MJ; Poschmann G; Petzsch P; Wiek C; Stühler K; Köhrer K; Schulz WA; Niegisch G
Sci Data; 2022 May; 9(1):240. PubMed ID: 35624179
[TBL] [Abstract][Full Text] [Related]
34. Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells.
Rosik L; Niegisch G; Fischer U; Jung M; Schulz WA; Hoffmann MJ
Cancer Biol Ther; 2014 Jun; 15(6):742-57. PubMed ID: 24618845
[TBL] [Abstract][Full Text] [Related]
35. HTP Nutraceutical Screening for Histone Deacetylase Inhibitors and Effects of HDACis on Tumor-suppressing miRNAs by Trichostatin A and Grapeseed (Vitis vinifera) in HeLa cells.
Mazzio EA; Soliman KF
Cancer Genomics Proteomics; 2017 Jan; 14(1):17-33. PubMed ID: 28031235
[TBL] [Abstract][Full Text] [Related]
36. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
37. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
38. Structure of 'linkerless' hydroxamic acid inhibitor-HDAC8 complex confirms the formation of an isoform-specific subpocket.
Tabackman AA; Frankson R; Marsan ES; Perry K; Cole KE
J Struct Biol; 2016 Sep; 195(3):373-378. PubMed ID: 27374062
[TBL] [Abstract][Full Text] [Related]
39. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
[TBL] [Abstract][Full Text] [Related]
40. FOXO3a Activation by HDAC Class IIa Inhibition Induces Cell Cycle Arrest in Pancreatic Cancer Cells.
Usami M; Kikuchi S; Takada K; Ono M; Sugama Y; Arihara Y; Hayasaka N; Nakamura H; Ikeda Y; Hirakawa M; Yoshida M; Miyanishi K; Kobune M; Kato J
Pancreas; 2020 Jan; 49(1):135-142. PubMed ID: 31856089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
